Bergsteinsson brings expertise and leadership in healthcare financing, capital markets and strategic transactions as Affini-T continues to build upon its strong foundation

Affini-T Therapeutics, Inc., a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, today announced the appointment of Kathy Bergsteinsson, MBA, as Chief Financial Officer. Bergsteinsson brings more than two decades of financial markets and strategic advisory experience, most recently as Managing Director and Head of Healthcare Equity Capital Markets at Morgan Stanley where she raised over $100 billion in equity financing for clients to help drive growth and innovation.

“Kathy’s broad financing, strategic planning and leadership expertise will be instrumental for us as we continue to grow our organization and transition our KRAS-targeting therapies into clinical investigation,” said Jak Knowles, M.D., Co-founder, President and Chief Executive Officer, Affini-T Therapeutics. “We are thrilled to have her join our experienced management team at this critical juncture and are excited to collaborate to advance potentially paradigm-shifting treatments for patients with hard-to-treat solid tumors.”

Bergsteinsson joins Affini-T after 17 years at Morgan Stanley, where she led the healthcare equity capital markets business for over a decade through a period of extraordinary growth. During her tenure, she managed over 70 initial public offerings and 175 follow-on common stock offerings, convertible debt offerings and private placement transactions for clients across the healthcare landscape. She began her time at Morgan Stanley in the merger and acquisitions department where she advised on more than $100 billion in strategic transactions. Bergsteinsson earned her Bachelor of Science degree in industrial engineering from Stanford University and her Master of Business Administration from The Wharton School at The University of Pennsylvania.

“I am incredibly excited to join this team and help grow the company as it leads the next frontier in precision immunotherapy for cancer,” said Bergsteinsson. “I was attracted to Affini-T for several reasons – compelling science, its passionate and experienced team and its mission to not just treat solid tumor patients, but potentially cure them with durable therapies. I am looking forward to guiding the company through its next phase of progress and clinical milestones.”

About Affini-T Therapeutics

Affini-T is a leading precision immunotherapy company targeting core oncogenic driver mutations to develop potentially curative therapies for patients with solid tumors. Our differentiated cell therapy platforms harness state-of-the-art engineering, synthetic biology, and gene editing capabilities to target even the most devastating cancer-driving mutations, beginning with KRAS. We leverage these tools to optimize T cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. Building on the world-class innovation inherent in our leadership team, founders and technologies, we are powered to develop transformational medicines that last. For more information, visit affinittx.com and follow us on LinkedIn and X, formerly known as Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231113388652/en/